Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics files a resale prospectus to register 2,522,727 shares of common stock for resale by selling stockholders. The registration covers 2,522,727 shares issued in a private placement on January 30, 2026 and states the Company will not receive any proceeds from resales.
The prospectus notes 23,457,183 shares outstanding as of March 10, 2026 and discloses a Nasdaq last sale price of $4.27 on March 19, 2026. The registration permits the selling stockholders to sell shares in various manners described under the Plan of Distribution.
Coya Therapeutics, Inc. registers for resale 2,522,727 shares of common stock issued in a January 29, 2026 private placement. The prospectus states these Shares were issued in the Private Placement at $4.40 per share and that the Company will receive no proceeds from resales by the selling stockholders.
The filing lists selling holders (including Greenlight Capital and Dr. Reddy’s), describes allowable methods of resale, and confirms the Company will pay registration expenses. Shares outstanding were 23,457,183 as of March 10, 2026.
Coya Therapeutics, Inc. is a clinical-stage biotech focused on therapies that enhance regulatory T cells to treat neurodegenerative, autoimmune and metabolic diseases. Its lead biologic, COYA 302, is in a Phase 2 ALSTARS trial for ALS after FDA IND acceptance, with an additional IND cleared for frontotemporal dementia. The company is also advancing COYA 303 and the low-dose IL-2 backbone COYA 301, plus Treg-derived exosome programs.
Coya reported a 2025 net loss of $21.2 million, up from $14.9 million in 2024, and an accumulated deficit of $62.0 million as of December 31, 2025. In January 2026 it raised $11.1 million in gross proceeds, including $10 million from strategic collaborator Dr. Reddy's, and expects its cash runway to extend into the second half of 2027. Management nonetheless states it will need substantial additional capital and highlights going-concern uncertainty if funding is not obtained.
Coya Therapeutics reported full-year 2025 results alongside a broad corporate update. Collaboration revenue rose to $7.9M from $3.6M, mainly from $6.7M of license milestones tied to its COYA 302 ALS program. Operating expenses increased to $30.5M, driven by higher clinical and R&D spending and greater general and administrative costs.
Net loss widened to $21.2M from $14.9M, reflecting heavier investment in development. Cash and cash equivalents were $46.8M at year-end. The company completed a $23.0M upsized public offering and an $11.1M private placement, extending its stated cash runway into the second half of 2027.
Coya advanced COYA 302 into the ALSTARS Phase 2 ALS trial across roughly 25 sites in the U.S. and Canada, received FDA and Health Canada clearances for new indications, and reported supportive translational and preclinical data for COYA 302 and COYA 303. Multiple clinical and publication milestones are targeted through 2026.
Dr. Reddy's Laboratories reported beneficial ownership of 2,272,727 shares of Coya Therapeutics, Inc. common stock, representing 9.7% of the class. The shares are directly held by Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories Limited are disclosed as potentially deemed beneficial owners through the corporate chain.
The filing cites 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026 in related issuer reports; the ownership table shows sole voting and dispositive power for the 2,272,727 shares.
The Vanguard Group reported beneficial ownership of 899,140 shares of Coya Therapeutics Inc common stock, representing 4.29% of the class as of December 31, 2025. Vanguard has shared voting power over 117,776 shares and shared dispositive power over all 899,140 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single other person has more than 5% interest in these securities. Vanguard notes an internal realignment on January 12, 2026, after which certain subsidiaries may report beneficial ownership separately while pursuing the same investment strategies.
Coya Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 2,522,727 common shares at $4.40 per share, raising approximately $11.1 million in gross proceeds. The investors are Dr. Reddy’s Labs, contributing $10.0 million, and Greenlight Capital, an existing institutional stockholder, contributing $1.1 million.
The company plans to use the net proceeds to transfer and scale manufacturing of low dose IL‑2 and accelerate manufacturing programs needed for commercial readiness of COYA 302. Management states these funds are expected to support accelerated commercial readiness plans while reiterating cash runway guidance into the second half of 2027 and past the projected topline for the ALSTARS trial.
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.
Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026. The award covers 140,041 stock options, each giving the right to buy one share of common stock at an exercise price of $4.73 per share.
The options vest in monthly installments over 36 months, as long as the executive continues to serve through each vesting date. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics, Inc. reported that Chief Medical Officer Fred Grossman received a grant of stock options to purchase 140,041 shares of common stock at an exercise price of $4.73 per share. The options were awarded at no cash cost at grant and are held directly. Subject to continuous service, the shares underlying the option vest in monthly installments over the next 36 months. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended effective November 17, 2022.